Shire Submits New Drug Application to FDA for Hemophilia A Gene Therapy – Rare Disease Report
Rare Disease Report |
Shire Submits New Drug Application to FDA for Hemophilia A Gene Therapy
Rare Disease Report An investigational new drug application was submitted to the U.S. Food and Drug Administration (FDA) by the leading biotechnology company Shire for its compound SHP654, also designated as BAX 888, an investigational factor VIII (FVIII) gene therapy for … Shire applies to test haemophilia A gene therapy in humans … Shire Asks FDA for a Designation That Will Lead to More Clinical Trials of Its Hemophilia A Therapy SHP654 Shire submits IND for hemophilia A treatment in US … |
